Cargando…
Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient's risk of cervical cancer. Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to achieve targeted inhibition of vira...
Autores principales: | Chang, J T-C, Kuo, T-F, Chen, Y-J, Chiu, C-C, Lu, Y-C, Li, H-F, Shen, C-R, Cheng, A-J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994641/ https://www.ncbi.nlm.nih.gov/pubmed/20885450 http://dx.doi.org/10.1038/cgt.2010.38 |
Ejemplares similares
-
Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells
por: Hong, D, et al.
Publicado: (2009) -
HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer
por: Amaro-Filho, Sérgio Menezes, et al.
Publicado: (2018) -
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
por: Morrow, Matthew P, et al.
Publicado: (2016) -
Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy
por: Chen, Junyu, et al.
Publicado: (2021) -
siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy
por: Shiri Aghbash, Parisa, et al.
Publicado: (2023)